EuroAPI overhaul comes into focus with plans to cut 550 staffers and divest two facilities

Anna Brown

News Reporter

Sanofi spin-off EuroAPI provided further details on its restructuring plan, with the company cutting 550 staffers and divesting two facilities — one in Brindisi, Italy, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EuroAPI overhaul comes into focus with plans to cut 550 staffers and divest two facilities

Anna Brown

News Reporter

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Eu­roAPI over­haul comes in­to fo­cus with plans to cut 550 staffers and di­vest two fa­cil­i­ties

Anna Brown

News Reporter

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

EuroAPI overhaul comes into focus with plans to cut 550 staffers and divest two facilities

Applied Therapeutics' rare disease drug gets a CRL

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam